BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+13.81%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.53B
AUM Growth
+$567M
(+8.1%)
Cap. Flow
-$9.29M
Cap. Flow
% of AUM
-0.12%
Top 10 Holdings %
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13
Top Buys
| 1 |
Incyte
INCY
|
$17.1M |
| 2 |
Intuitive Surgical
ISRG
|
$15.7M |
| 3 |
DexCom
DXCM
|
$14.5M |
| 4 |
Centene
CNC
|
$13.5M |
| 5 |
Abbott
ABT
|
$12.6M |
Top Sells
| 1 |
ABMD
Abiomed Inc
ABMD
|
$40.9M |
| 2 |
UnitedHealth
UNH
|
$38.4M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$32.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
Molina Healthcare
MOH
|
$18M |
Sector Composition
| 1 | Healthcare | 99.55% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Fate Therapeutics
FATE
$110M
| $49.1M | 0.65% |
4,861,279
+1,115,193
| +30% | +$11.3M |
|
52
Medtronic
MDT
$120B
| $48.1M | 0.64% |
618,420
+2,494
| +0.4% | +$194K |
|
53
Bio-Rad Laboratories Class A
BIO
$7.77B
| $46.7M | 0.62% |
111,158
+9,340
| +9% | +$3.93M |
|
54
Halozyme
HALO
$8.69B
| $46.2M | 0.61% |
812,700
-117,800
| -13% | -$6.7M |
|
55
Thermo Fisher Scientific
TMO
$183B
| $45.9M | 0.61% |
83,329
+11,185
| +16% | +$6.16M |
|
56
Idexx Laboratories
IDXX
$51.2B
| $44.4M | 0.59% |
108,822
| – | – |
|
57
Exelixis
EXEL
$10B
| $42.9M | 0.57% |
2,673,500
| – | – |
|
58
Transmedics
TMDX
$3.48B
| $42.1M | 0.56% |
682,058
+28,244
| +4% | +$1.74M |
|
59
Pfizer
PFE
$140B
| $40.4M | 0.54% |
788,673
+21,373
| +3% | +$1.1M |
|
60
IQVIA
IQV
$31B
| $37.6M | 0.5% |
183,320
+23,093
| +14% | +$4.73M |
|
61
CRISPR Therapeutics
CRSP
$4.74B
| $37.1M | 0.49% |
911,705
-16,600
| -2% | -$675K |
|
62
CareDx
CDNA
$684M
| $36.2M | 0.48% |
3,168,448
+567,002
| +22% | +$6.47M |
|
63
Zimmer Biomet
ZBH
$20.8B
| $34M | 0.45% |
266,296
+1,026
| +0.4% | +$131K |
|
64
Axsome Therapeutics
AXSM
$6.11B
| $33.7M | 0.45% |
436,658
-59,866
| -12% | -$4.62M |
|
65
BioNTech
BNTX
$24.5B
| $33.2M | 0.44% |
221,080
+67,500
| +44% | +$10.1M |
|
66
Harmony Biosciences
HRMY
$2.11B
| $32.9M | 0.44% |
596,192
-60,996
| -9% | -$3.36M |
|
67
Wave Life Sciences
WVE
$1.25B
| $31.5M | 0.42% |
4,494,458
| – | – |
|
68
Procept Biorobotics
PRCT
$2.11B
| $30.8M | 0.41% |
741,517
+152,255
| +26% | +$6.32M |
|
69
Veeva Systems
VEEV
$43.9B
| $30.1M | 0.4% |
186,257
+28,666
| +18% | +$4.63M |
|
|
ACCD
70
DELISTED
Accolade, Inc. Common Stock
ACCD
| $28.6M | 0.38% |
3,677,277
+105,407
| +3% | +$821K |
|
71
AtriCure
ATRC
$1.77B
| $28.6M | 0.38% |
644,109
+1,662
| +0.3% | +$73.8K |
|
72
HUTCHMED
HCM
$2.54B
| $28.4M | 0.38% |
1,780,144
+22,069
| +1% | +$352K |
|
73
Beam Therapeutics
BEAM
$1.83B
| $27.2M | 0.36% |
696,721
+125,000
| +22% | +$4.89M |
|
74
Esperion Therapeutics
ESPR
$488M
| $27M | 0.36% |
4,330,264
+105,000
| +2% | +$654K |
|
75
Cooper Companies
COO
$13.3B
| $26.9M | 0.36% |
325,252
| – | – |
|